Dietary supplement for hair loss in women using GLP-1 weight-loss drugs
Part of Skin clinical trials.
This study is testing whether a special dietary supplement can help women who are losing hair after using GLP-1 weight-loss drugs (like semaglutide or tirzepatide). If you are a woman aged 20-60 on a GLP-1 medication and have noticed increased hair shedding, you might be eligible to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 20 and 60 years old.
- You have been taking a GLP-1 weight-loss medication (like semaglutide or tirzepatide) for at least 3 months.
- You have been diagnosed with telogen effluvium (a type of temporary hair shedding) linked to that medication.
- Your hair is at least 3 centimeters (about 1.2 inches) long.
- You have not used other hair-loss treatments (like minoxidil, finasteride, or supplements) in the last 3 months.
- You have no active scalp conditions (like psoriasis, eczema, or severe dandruff) and have not had hair chemical treatments (like dyeing or perming) in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special drinkable supplement can help prevent or reduce hair loss in women who are taking a GLP-1 or GIP receptor agonist (a type of weight-loss or diabetes medication). The study looks for women who have just started this medication or have been on it for less than 3 months.
This trial tests whether a combination of a dietary supplement and a topical serum can help women with thinning hair grow thicker, fuller hair. It's designed for women who have noticed mild to moderate hair thinning and want a non-invasive approach.
This study tests whether a dietary supplement helps hair growth in men with mild to moderate male pattern baldness. It lasts 6 months, and you will not know if you are getting the real supplement or a placebo.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests whether switching to an oral weight-loss medication can help you keep off the weight you lost after stopping a GLP-1 injection like semaglutide or tirzepatide. You might qualify if you live in Massachusetts, are between 18 and 80, have a BMI of 30 or higher, lost at least 10% of your body weight on these injections, and are willing to be randomly assigned to a new treatment.
This study tests a nasal spray containing semaglutide (a GLP-1 receptor agonist) to see if it helps adults who are overweight or obese lose weight. It may be an option if you have a BMI between 27 and 35 and have not used other weight loss medications recently.
Hear when a new Alopecia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.